Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study (Q30544631)

18 August 2017

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study (English)

1 reference

18 August 2017

0 references

1 reference

Ming-Sound Tsao

4

0 references

David R Gandara

12

object named as

David Gandara

1 reference

18 August 2017

6

James Jett

1 reference

18 August 2017

Glenwood D Goss

1

1 reference

18 August 2017

Chris O'Callaghan

2

1 reference

18 August 2017

Ian Lorimer

3

1 reference

18 August 2017

Gregory A Masters

5

1 reference

18 August 2017

Martin J Edelman

7

1 reference

18 August 2017

Rogerio Lilenbaum

8

1 reference

18 August 2017

Hak Choy

9

1 reference

18 August 2017

Fadlo Khuri

10

1 reference

18 August 2017

Katherine Pisters

11

1 reference

18 August 2017

Kemp Kernstine

13

1 reference

18 August 2017

Charles Butts

14

1 reference

18 August 2017

Jonathan Noble

15

1 reference

18 August 2017

Thomas A Hensing

16

1 reference

18 August 2017

Kendrith Rowland

17

1 reference

18 August 2017

Joan Schiller

18

1 reference

18 August 2017

Keyue Ding

19

1 reference

18 August 2017

Frances A Shepherd

20

1 reference

18 August 2017

language of work or name

English

0 references

publication date

26 August 2013

1 reference

Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

31

1 reference

18 August 2017

27

1 reference

18 August 2017

3320-3326

1 reference

EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Screening for epidermal growth factor receptor mutations in lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Erlotinib in previously treated non-small-cell lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

EGFR and cancer prognosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Revisions in the International System for Staging Lung Cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3770864

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23980091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evidence for a role of EGF receptor in the progression of human lung carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23980091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23980091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2013.51.1816

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23980091

1 reference